# A Study to Investigate the Safety and Efficacy of Fidaxomicin (Oral Suspension or Tablets) and Vancomycin (Oral Liquid or Capsules) in Pediatric Subjects With Clostridium Difficile-associated Diarrhea (CDAD)

> **NCT02218372** · PHASE3 · COMPLETED · sponsor: **Astellas Pharma Europe B.V.** · enrollment: 148 (actual)

## Conditions studied

- Clostridium Difficile-associated Diarrhea (CDAD)

## Interventions

- **DRUG:** Fidaxomicin oral suspension
- **DRUG:** Fidaxomicin tablets
- **DRUG:** Vancomycin oral liquid
- **DRUG:** Vancomycin capsules

## Key facts

- **NCT ID:** NCT02218372
- **Lead sponsor:** Astellas Pharma Europe B.V.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-01-09
- **Primary completion:** 2018-03-07
- **Final completion:** 2018-03-07
- **Target enrollment:** 148 (ACTUAL)
- **Last updated:** 2024-11-26

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02218372

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02218372, "A Study to Investigate the Safety and Efficacy of Fidaxomicin (Oral Suspension or Tablets) and Vancomycin (Oral Liquid or Capsules) in Pediatric Subjects With Clostridium Difficile-associated Diarrhea (CDAD)". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02218372. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*